FluoroPharma Medical, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today after the closing bell announced that it has appointed Thijs Spoor to the position of Chairman of the Board. Mr. Spoor will also continue to hold the positions of President and CEO as he assumes the role formerly held by Dr. David Elmaleh.
Mr. Spoor was appointed President and CEO of FluoroPharma Inc. on September 15, 2010. Prior to joining the company, he was the CFO of Sunstone BioSciences. He also worked as a consultant at Oliver Wyman, primarily engaging with pharmaceutical and medical device companies. Additionally, Mr. Spoor has been an equity research analyst at J.P. Morgan and Credit Suisse, covering the Biotechnology and Medical Device industries. Mr. Spoor also worked with Amersham / GE Healthcare where he oversaw the nuclear cardiology portfolio and most recently as the Director of New Product Opportunities leading the PET strategic plan.
Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting.
For more information, see the company website at www.FluoroPharma.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html